Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation model. A multifaceted approach is needed to reduce financial barriers to obesity ...

Tirzepatide combined with lifestyle modification reduced the highest number of obesity cases (45,609 per 100,000 eligible individuals), diabetes cases (20,854 per 100,000 eligible individuals ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials. OSA is a prevalent ...

Not only that, but the drug also has another mechanism of action [MOA] at the same time of helping patients lose weight, while providing an improvement for MASH. Beyond this, the company also has ...

Tirzepatide-associated weight loss was partially mediated by gastrointestinal adverse events. Some of the weight reduction observed with tirzepatide is associated with gastrointestinal (GI) adverse ...

About The Study: This economic evaluation found that although tirzepatide and semaglutide offered substantial long-term health benefits, they were not cost-effective at current net prices. Efforts to ...